

Albert Perez Garcia-Romeu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8225824/publications.pdf>

Version: 2024-02-01

39
papers

2,747
citations

393982

19
h-index

315357

38
g-index

41
all docs

41
docs citations

41
times ranked

1265
citing authors

#	ARTICLE	IF	CITATIONS
1	Ancient Roots of Today's Emerging Renaissance in Psychedelic Medicine. <i>Culture, Medicine and Psychiatry</i> , 2022, 46, 890-903.	0.7	11
2	Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 983-996.	1.3	22
3	We Need Better Estimates of Kratom Use Prevalence. <i>American Journal of Preventive Medicine</i> , 2022, 62, 132-133.	1.6	9
4	Understanding Kratom Use: A Guide for Healthcare Providers. <i>Frontiers in Pharmacology</i> , 2022, 13, 801855.	1.6	30
5	Toward Synergies of Ketamine and Psychotherapy. <i>Frontiers in Psychology</i> , 2022, 13, 868103.	1.1	18
6	Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. <i>Neuropharmacology</i> , 2022, 214, 109127.	2.0	7
7	Need for Clarity and Context in Case Reports on Kratom Use, Assessment, and Intervention. <i>Substance Abuse</i> , 2022, 43, 1221-1224.	1.1	8
8	Kratom use as more than a "self-treatment". <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 684-694.	1.1	20
9	Kratom use in the United States: a diverse and complex profile. <i>Addiction</i> , 2021, 116, 202-203.	1.7	14
10	A commentary from the CPDD Underrepresented Populations Committee: New CPDD member survey to accelerate progress in equity, inclusion and diversity. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108380.	1.6	0
11	Advancing equity, diversity, and inclusion in the American College of Neuropsychopharmacology (ACNP): advances, challenges, and opportunities to accelerate progress. <i>Neuropsychopharmacology</i> , 2021, 46, 871-876.	2.8	7
12	Reply to Drs. Hart and Cadet: we agree "the challenges of increasing equity, diversity and inclusion include societal issues and actions now are vital. <i>Neuropsychopharmacology</i> , 2021, 46, 878-879.	2.8	0
13	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. <i>Journal of Psychopharmacology</i> , 2021, 35, 353-361.	2.0	49
14	Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. <i>Drugs: Education, Prevention and Policy</i> , 2021, 28, 211-214.	0.8	23
15	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 615-623.	1.0	20
16	Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 444-454.	1.1	18
17	Recent Progress in Lyme Disease and Remaining Challenges. <i>Frontiers in Medicine</i> , 2021, 8, 666554.	1.2	55
18	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. <i>International Journal of Drug Policy</i> , 2021, 98, 103380.	1.6	21

#	ARTICLE	IF	CITATIONS
19	Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color. <i>Chronic Stress</i> , 2021, 5, 247054702110356.	1.7	19
20	Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 472-478.	2.5	51
21	Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 553-561.	0.7	7
22	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 287-317.	0.8	11
23	Current and Future Potential Impact of COVID-19 on Kratom (<i>Mitragyna speciosa</i> Korth.) Supply and Use. <i>Frontiers in Psychiatry</i> , 2020, 11, 574483.	1.3	5
24	Kratom (<i>Mitragyna speciosa</i>): User demographics, use patterns, and implications for the opioid epidemic. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107849.	1.6	98
25	Cessation and reduction in alcohol consumption and misuse after psychedelic use. <i>Journal of Psychopharmacology</i> , 2019, 33, 1088-1101.	2.0	145
26	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. <i>Frontiers in Psychiatry</i> , 2019, 10, 955.	1.3	75
27	T263. Psilocybin Improves Cognitive Control and Downregulates Parietal Cortex in Treatment-Seeking Smokers. <i>Biological Psychiatry</i> , 2018, 83, S231-S232.	0.7	2
28	Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. <i>International Review of Psychiatry</i> , 2018, 30, 291-316.	1.4	115
29	Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. <i>Journal of Psychopharmacology</i> , 2018, 32, 756-769.	2.0	152
30	Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions. <i>Frontiers in Psychiatry</i> , 2018, 9, 34.	1.3	27
31	An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. <i>Journal of Psychopharmacology</i> , 2017, 31, 841-850.	2.0	72
32	Long-term follow-up of psilocybin-facilitated smoking cessation. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 55-60.	1.1	430
33	Clinical applications of hallucinogens: A review.. <i>Experimental and Clinical Psychopharmacology</i> , 2016, 24, 229-268.	1.3	130
34	Self-transcendent experience: a grounded theory study. <i>Qualitative Research</i> , 2015, 15, 633-654.	2.2	39
35	The subjective experience of acute, experimentally-induced <i>Salvia divinorum</i> inebriation. <i>Journal of Psychopharmacology</i> , 2015, 29, 426-435.	2.0	29
36	Does Mindfulness Meditation Increase Effectiveness of Substance Abuse Treatment with Incarcerated Youth? A Pilot Randomized Controlled Trial. <i>Mindfulness</i> , 2015, 6, 1472-1480.	1.6	45

#	ARTICLE	IF	CITATIONS
37	Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. <i>Current Drug Abuse Reviews</i> , 2015, 7, 157-164.	3.4	306
38	Exploring an intensive meditation intervention for incarcerated youth. <i>Child and Adolescent Mental Health</i> , 2014, 19, 69-73.	1.8	43
39	Pilot study of the 5-HT _{2A} agonist psilocybin in the treatment of tobacco addiction. <i>Journal of Psychopharmacology</i> , 2014, 28, 983-992.	2.0	613